Pharmacological management of anticholinergic delirium ‐ theory, evidence and practice
Open Access
- 21 November 2015
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 81 (3) , 516-524
Abstract
The spectrum of anticholinergic delirium is a common complication following drug overdose. Patients with severe toxicity can have significant distress and behavioural problems that often require pharmacological management. Cholinesterase inhibitors, such as physostigmine, are effective but widespread use has been limited by concerns about safety, optimal dosing and variable supply. Case series support efficacy in reversal of anticholinergic delirium. However doses vary widely and higher doses commonly lead to cholinergic toxicity. Seizures are reported in up to 2.5% of patients and occasional cardiotoxic effects are also recorded.This article reviews the serendipitous path whereby physostigmine evolved into the preferred anticholinesterase antidote largely without any research to indicate the optimal dosing strategy. Adverse events observed in case series should be considered in the context of pharmacokinetic/pharmacodynamic studies of physostigmine which suggest a much longer latency before the maximal increase in brain acetylcholine than had been previously assumed. This would favour protocols that use lower doses and longer re‐dosing intervals. We propose based on the evidence reviewed that the use of cholinesterase inhibitors should be considered in anticholinergic delirium that has not responded to non‐pharmacological delirium management. The optimal risk/benefit would be with a titrated dose of 0.5 to 1 mg physostigmine (0.01–0.02 mg kg−1in children) with a minimum delay of 10–15 min before re‐dosing. Slower onset and longer acting agents such as rivastigmine would also be logical but more research is needed to guide the appropriate dose in this setting.Keywords
This publication has 69 references indexed in Scilit:
- A one-year observational study of all hospitalized and fatal acute poisonings in Oslo: Epidemiology, intention and follow-upBMC Public Health, 2012
- The Selective M1 Muscarinic Cholinergic Agonist CDD-0102A Enhances Working Memory and Cognitive FlexibilityThe Journal of Pharmacology and Experimental Therapeutics, 2012
- Acute Human Lethal Toxicity of Agricultural Pesticides: A Prospective Cohort StudyPLOS Medicine, 2010
- Psychotropic drugs in the Cervantine textsJournal of the Royal Society of Medicine, 2008
- Cholinesterase Inhibitors in the Treatment of Alzheimer??s DiseaseDrug Safety, 1998
- Inhibition of Acetylcholinesterase Activity in Human Brain Tissue and Erythrocytes by Galanthamine, Physostigmine and TacrineClinical Chemistry and Laboratory Medicine (CCLM), 1991
- The Molecular Basis of Anticholinesterase Actions on Nicotinic and Glutamatergic SynapsesaAnnals of the New York Academy of Sciences, 1987
- Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patientsActa Anaesthesiologica Scandinavica, 1986
- Effects of self poisoning with maprotiline.BMJ, 1984
- Asystole complicating physostigmine treatment of tricyclic antidepressant overdoseAnnals of Emergency Medicine, 1980